Researchers at Karolinska Institutet and five Chinese hospitals have reversed congenital deafness in all 10 participants of a clinical trial using a single injection of gene therapy. The treatment delivers a working copy of the OTOF gene into the inner ear via a synthetic virus, restoring production of otoferlin — a protein essential for transmitting sound signals to the brain.
Results were dramatic: most patients began hearing within one month, and after six months the average detectable sound level improved from 106 decibels to 52. A seven-year-old girl regained nearly full hearing and could hold everyday conversations with her mother four months after treatment. The therapy was well-tolerated with no serious side effects during 6–12 months of follow-up.
The findings, published in Nature Medicine, open the door to treating other genetic forms of deafness. The team is already expanding work to target GJB2 and TMC1, two more common genes linked to hearing loss.
